Valuation: Pharmaniaga

Market Cap 1.56B 386M 330M 308M 283M 531M 36.91B 542M 3.66B 1.43B 18.5B 1.45B 1.42B 61.24B P/E 2026 *
19.7x
P/E 2027 * 17.4x
Enterprise Value 1.56B 386M 330M 308M 283M 531M 36.91B 542M 3.66B 1.43B 18.5B 1.45B 1.42B 61.24B EV / Sales 2026 *
0.38x
EV / Sales 2027 * 0.37x
Free-Float
37.97%
Yield 2026 *
12.8%
Yield 2027 * 17.2%
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Member of Audit Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces Appointment of Mohd Firdaus Bin Zulkifli as A Member of Nomination and Remuneration Committee, Effective August 17, 2026 CI
08-13 Pharmaniaga Berhad Announces second Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 13 October 2026 CI
08-13 Pharmaniaga Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-17 Pharmaniaga Berhad Announces Redesignation of Dato' Dr Faridah Aryani Binti Md Yusof from Member of Risk Committee to Independent and Non Executive Chairman of Risk Committee, Effective 16 July 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Redesignation of Encik Mohd Firdaus Bin Zulkifli as Non Independent and Non Executive Director from Alternate Director, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Chairman of the Risk Committee, Effective July 1, 2026 CI
06-30 Pharmaniaga Berhad Announces Resignation of Mohd Zahir Bin Zahur Hussain as Member of the Nomination and Remuneration Committee, Effective July 1, 2026 CI
06-10 Pharmaniaga Completes 5:1 Share Consolidation MT
05-28 Pharmaniaga says government of Malaysia accepts unit's tender to supply insulin for 3 years RE
05-18 Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ended 31 December 2026, Payable on 03 July 2026 CI
1 day+0.84%
1 week+1.69%
Current month+1.69%
1 month+0.84%
3 months-2.04%
6 months-23.81%
Current year-15.79%
1 week 1.16
Extreme 1.16
1.22
1 month 1.15
Extreme 1.15
1.22
Current year 1.12
Extreme 1.12
1.7
1 year 0.82
Extreme 0.825
1.7
3 years 0.65
Extreme 0.65
2.55
5 years 0.65
Extreme 0.65
4.72
10 years 0.65
Extreme 0.65
7.25
Manager TitleAgeSince
Chief Executive Officer 53 01/09/2024
Director of Finance/CFO 59 01/06/2012
Chief Administrative Officer 53 01/10/2024
Director TitleAgeSince
Director/Board Member 55 20/11/2020
Director/Board Member 53 01/03/2024
Director/Board Member 51 20/08/2021
Date Insider Type Main position Quantity % Market Cap.
27/03/26 Buy

Director

300,000 0.0046%
Change 5-day change 1-year change 3-year change Capi.($)
+0.84%+1.69%+33.33%-40.00% 386M
-1.75%-2.09%+19.32%+99.50% 97.79B
-2.72%-1.20%+49.37%+166.12% 53.13B
0.00%-2.68%+1.75%+279.08% 23.75B
+1.77%-0.72%-12.41%-13.45% 8.28B
+4.98%+1.22%-34.67%-20.49% 7.8B
-0.54%-1.20%-16.16%-23.96% 6.6B
-4.19%-3.14%+4.58%+16.10% 6.29B
+2.35%+2.29%-2.88%+19.42% 5.16B
+1.21%+3.32%+9.48%+19.20% 3.72B
Average +0.20%-0.25%+5.17%+50.15% 21.29B
Weighted average by Cap. -1.29%-1.54%+19.43%+117.48%

Financials

2026 *2027 *
Net sales 4.13B 1.02B 875M 816M 749M 1.41B 97.76B 1.44B 9.68B 3.77B 48.99B 3.84B 3.75B 162B 4.26B 1.05B 902M 842M 772M 1.45B 101B 1.48B 9.98B 3.89B 50.52B 3.96B 3.87B 167B
Net income 93.3M 23.06M 19.75M 18.42M 16.91M 31.77M 2.21B 32.39M 219M 85.2M 1.11B 86.6M 84.72M 3.66B 113M 27.93M 23.91M 22.31M 20.47M 38.46M 2.67B 39.22M 265M 103M 1.34B 105M 103M 4.43B
Net Debt - -
Logo Pharmaniaga
Pharmaniaga Berhad is an investment holding company engaged in the provision of management services to its subsidiaries. The Company’s segments include Manufacturing, Logistics and distribution, and Indonesia. The Manufacturing segment is engaged in manufacturing of pharmaceutical products in Malaysia. The Logistics and distribution segment includes distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Indonesia segment is engaged in manufacturing and distribution of pharmaceutical and medical products in Indonesia. Its product portfolio comprises oral solid dosages, liquid, cream and small volume injectables. It also manufactures general pharmaceuticals, including penicillin, cephalosporin and over-the-counter products. Its research and development capabilities include drug formulation and analytical development, process scale-up, clinical research and product localization.
Employees
3,502
Date Price Change Volume
21/08/26 MYR 1.200 +0.84% 1,366,500
20/08/26 MYR 1.190 0.00% 14,271,100
19/08/26 MYR 1.190 0.00% 1,907,500
18/08/26 MYR 1.190 +0.85% 3,259,700
17/08/26 MYR 1.180 0.00% 1,968,400
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.190MYR
Average target price
1.530MYR
Spread / Average Target
+28.57%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7081 Stock